Document is current

Article History

Received: 10 February 2025

Accepted: 28 March 2025

First Online: 18 April 2025

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki. All participants provided written consent, and the protocol was approved by the Danish National Committee on Health Research Ethics (H-19063311).

: Not applicable.

: PR has received speaking fees and/or consultancy to Steno Diabetes Center Copenhagen from Eli Lilly, Novo Nordisk, Sanofi Aventis, Vifor, Boehringer Ingelheim, Astellas, Gilead, Bayer, AstraZeneca, Mundipharma, and MSD. PR has received research grants from Novo Nordisk AstraZeneca. PR, TWH and RSR had shares in Novo Nordisk. AK and RSR has received consultancy fees from Novo Nordisk. EHZ is a full-time employee in Novo Nordisk and has shares in Novo Nordisk. IKR is a full-time employee at Novo Nordisk. ML: has received speaker and consultancy fees from AstraZeneca, Bayer, Boeringer Ingelheim, Novo Nordisk, GlaxoSmithKline, and is an investigator in clinical studies sponsored by Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, MSD and Novo Nordisk. JPG has served as consultant for Novo Nordisk on measurement of bioactive peptides. TBS has received research grants from Pfizer, Sanofi Pasteur, GSK, Novo Nordisk, AstraZeneca, Boston Scientific and GE Healthcare, consulting fees from Novo Nordisk, IQVIA, Parexel, Amgen, CSL Seqirus, GSK and Sanofi Pasteur, and lecture fees from Bayer, Novartis, Sanofi Pasteur, GE healthcare and GSK. The other authors declare that there is no duality of interest associated with this manuscript.